PP patients treated with iCombo after three months more often achieved ACR@ ( @ % vs @ % , P < @ ) , ACR@ ( @ % vs @ % , P < @ ) and ACR@ response ( @ % vs @ % , P < @ ) than those treated with iMono , and had more improvement in HAQ ( median decrease @ vs @ , P < @ ) .